
ANCN
Healthcare · Biotechnology · $34.9M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2020
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 9, 2021 | After the close | -1.60 | -0.05 | +96.9% |
| Nov 16, 2020 | After the close | -1.44 | -0.07 | +95.1% |
| Aug 14, 2020 | After the close | -1.28 | -0.09 | +93.0% |
| May 7, 2020 | After the close | -1.76 | -0.10 | +94.3% |
| Mar 17, 2020 | After the close | -2.00 | 0.29 | +114.5% |
| Nov 15, 2019 | After the close | -2.93 | -0.43 | +85.3% |
| Aug 5, 2019 | After the close | -2.64 | -0.05 | +98.1% |
| May 22, 2019 | After the close | -2.56 | -0.70 | +72.7% |
| Mar 12, 2019 | After the close | -2.40 | -0.07 | +97.1% |
Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapeutics. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/ß-catenin program, which identifies small molecules that…